Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Feb;65(2):257-60.
doi: 10.1136/ard.2005.039099. Epub 2005 Jun 23.

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

S N Nikas  1 , P V Voulgari, Y Alamanos, C G Papadopoulos, A I Venetsanopoulou, A N Georgiadis, A A Drosos
Affiliations
Comparative Study

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

S N Nikas et al. Ann Rheum Dis. 2006 Feb.

Abstract

Objective: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment.

Methods: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor alpha inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria.

Results: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months' adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study-two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study-one because of lack of efficacy and two owing to side effects.

Conclusion: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued.

PubMed Disclaimer

References

    1. Maini R, St Clair E W, Breedveld F, Kalden J, Weisman M, Smolen J.et al Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 19993541932–1939. - PubMed
    1. Arnett F C, Edworthy S M, Bloch D A, McShane D J, Fries J F, Cooper N S.et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 198831315–324. - PubMed
    1. Voulgari P V, Alamanos Y, Nikas S N, Bougias D V, Temekonidis T I, Drosos A A. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005118515–520. - PubMed
    1. Felson D T, Anderson J J, Boers M, Bombardier C, Furst D, Goldsmith C.et al American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 199538727–735. - PubMed
    1. Paulus H E, Egger M J, Ward J R, Williams H J. Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 199033477–484. - PubMed

Publication types

MeSH terms